Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$12.09 -3.6%	$12.72	$5.11 ▼ $19.22	$338.39M	1.03	234,185 shs	175,591 shs
LUNG Pulmonx	$2.96 -4.2%	$4.79	$2.83 ▼ $9.37	$119.16M	0.65	315,104 shs	350,640 shs
SMLR Semler Scientific	$41.32 -4.8%	$36.21	$21.77 ▼ $81.56	$460.80M	1.33	491,243 shs	857,363 shs
TMCI Treace Medical Concepts	$5.85 -3.9%	$7.09	$4.54 ▼ $10.79	$367.91M	0.79	605,542 shs	773,287 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	-3.59%	-0.58%	-17.81%	-14.86%	+119.42%
LUNG Pulmonx	-4.21%	-5.73%	-42.97%	-65.66%	-63.05%
SMLR Semler Scientific	-4.77%	-7.95%	+16.82%	+1.70%	+42.48%
TMCI Treace Medical Concepts	-3.94%	-7.00%	-15.22%	-35.93%	+15.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLPT ClearPoint Neuro	1.819 of 5 stars	3.5	2.0	2.6	0.0	0.6
LUNG Pulmonx	3.1364 of 5 stars	4.3	2.0	1.1	2.5	1.3
SMLR Semler Scientific	2.8505 of 5 stars	3.5	2.0	2.6	2.5	1.3
TMCI Treace Medical Concepts	2.3029 of 5 stars	3.1	1.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	3.00	Buy	$25.00	106.78% Upside
LUNG Pulmonx	2.67	Moderate Buy	$11.59	291.65% Upside
SMLR Semler Scientific	3.00	Buy	$71.00	71.83% Upside
TMCI Treace Medical Concepts	2.29	Hold	$10.16	73.63% Upside

Current Analyst Ratings Breakdown

Latest LUNG, SMLR, TMCI, and CLPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/9/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $8.60
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/11/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.50 ➝ $8.00
4/1/2025	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $25.00
3/13/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$10.00 ➝ $9.50
3/10/2025	LUNG Pulmonx	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
3/10/2025	LUNG Pulmonx	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight ➝ Equal Weight
3/10/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$32.24M	10.50	N/A	N/A	$0.86 per share	14.06
LUNG Pulmonx	$87.47M	1.36	N/A	N/A	$3.09 per share	0.96
SMLR Semler Scientific	$49.23M	9.36	$2.44 per share	16.95	$10.45 per share	3.95
TMCI Treace Medical Concepts	$210.82M	1.75	N/A	N/A	$2.24 per share	2.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$22.09M	-$0.76	N/A	N/A	N/A	-59.64%	-62.10%	-38.39%	8/6/2025 (Estimated)
LUNG Pulmonx	-$60.84M	-$1.44	N/A	N/A	N/A	-67.31%	-55.36%	-33.53%	7/30/2025 (Estimated)
SMLR Semler Scientific	$20.58M	-$2.61	8.42	∞	N/A	72.65%	50.77%	47.04%	8/4/2025 (Estimated)
TMCI Treace Medical Concepts	-$49.53M	-$0.85	N/A	N/A	N/A	-30.33%	-51.12%	-26.36%	8/5/2025 (Estimated)

Latest LUNG, SMLR, TMCI, and CLPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CLPT ClearPoint Neuro	-$0.15	-$0.22	-$0.07	-$0.22	$8.21 million	$8.49 million
5/13/2025	Q1 2025	SMLR Semler Scientific	N/A	-$0.76	N/A	-$6.74	N/A	$8.84 million
5/8/2025	Q1 2025	TMCI Treace Medical Concepts	-$0.31	-$0.25	+$0.06	-$0.25	$52.07 million	$52.57 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
SMLR Semler Scientific	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	N/A	4.54	3.61
LUNG Pulmonx	0.40	7.70	6.77
SMLR Semler Scientific	N/A	3.14	3.09
TMCI Treace Medical Concepts	0.51	4.12	2.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
LUNG Pulmonx	91.04%
SMLR Semler Scientific	49.37%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.97%
LUNG Pulmonx	6.80%
SMLR Semler Scientific	30.20%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	27.99 million	25.90 million	Optionable
LUNG Pulmonx	250	40.26 million	37.24 million	Optionable
SMLR Semler Scientific	120	11.15 million	6.47 million	Not Optionable
TMCI Treace Medical Concepts	250	62.89 million	47.08 million	Optionable

LUNG, SMLR, TMCI, and CLPT Headlines

Recent News About These Companies

The Gross Law Firm Notifies Treace Medical Concepts, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TMCI

May 29 at 5:45 AM | prnewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action – Contact Levi & Korsinsky

May 28 at 4:30 PM | accessnewswire.com

Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) Over Securities Violations - Contact Levi & Korsinsky Today

May 28 at 2:45 PM | accessnewswire.com

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

May 28 at 2:23 PM | globenewswire.com

Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Shareholders of Class Action Lawsuit and June 10, 2025 Deadline

May 28 at 12:15 PM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

May 28 at 12:00 PM | prnewswire.com

Shareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & Korsinsky

May 28 at 10:45 AM | accessnewswire.com

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Treace Medical Concepts, Inc. (TMCI)

May 28 at 7:15 AM | accessnewswire.com

TMCI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

May 28 at 7:00 AM | accessnewswire.com

TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors - Lead Plaintiff Deadline June 10, 2025

May 27 at 4:30 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 4:12 PM | markets.businessinsider.com

Class Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 27 at 2:40 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 2:23 PM | accessnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 10, 2025 - Treace Medical Concepts, Inc. (TMCI)

May 27 at 12:30 PM | accessnewswire.com

TMCI ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Treace Medical Concepts, Inc. - June 10, 2025 Deadline

May 27 at 11:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

May 27 at 10:45 AM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 10, 2025 Deadline

May 27 at 9:30 AM | accessnewswire.com

Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) - Contact Levi & Korsinsky Before June 10, 2025

May 27 at 8:45 AM | accessnewswire.com

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

May 27 at 8:30 AM | globenewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action - Contact Levi & Korsinsky

May 27 at 7:25 AM | accessnewswire.com

BNP Paribas Financial Markets Makes New $590,000 Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

May 26 at 3:21 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG, SMLR, TMCI, and CLPT Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$12.09 -0.45 (-3.59%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$12.20 +0.12 (+0.95%)

As of 06:27 AM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Pulmonx NASDAQ:LUNG

$2.96 -0.13 (-4.21%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.98 +0.02 (+0.51%)

As of 04:25 AM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Semler Scientific NASDAQ:SMLR

$41.32 -2.07 (-4.77%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$42.93 +1.61 (+3.91%)

As of 05:34 AM Eastern

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Treace Medical Concepts NASDAQ:TMCI

$5.85 -0.24 (-3.94%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$5.85 0.00 (0.00%)

As of 05/28/2025 04:04 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time